These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

456 related articles for article (PubMed ID: 30616755)

  • 21. Targeting EGFRvIII for glioblastoma multiforme.
    Yang J; Yan J; Liu B
    Cancer Lett; 2017 Sep; 403():224-230. PubMed ID: 28649003
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunotherapy of Primary Brain Tumors: Facts and Hopes.
    Buerki RA; Chheda ZS; Okada H
    Clin Cancer Res; 2018 Nov; 24(21):5198-5205. PubMed ID: 29871908
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Emerging immunotherapies for glioblastoma.
    Desai R; Suryadevara CM; Batich KA; Farber SH; Sanchez-Perez L; Sampson JH
    Expert Opin Emerg Drugs; 2016 Jun; 21(2):133-45. PubMed ID: 27223671
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunotherapy for Glioblastoma: Current Progress and Challenges.
    Yu MW; Quail DF
    Front Immunol; 2021; 12():676301. PubMed ID: 34054867
    [TBL] [Abstract][Full Text] [Related]  

  • 25. What next for newly diagnosed glioblastoma?
    Domingo-Musibay E; Galanis E
    Future Oncol; 2015; 11(24):3273-83. PubMed ID: 26558493
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Microglia in Cancer: For Good or for Bad?
    da Fonseca AC; Amaral R; Garcia C; Geraldo LH; Matias D; Lima FR
    Adv Exp Med Biol; 2016; 949():245-261. PubMed ID: 27714693
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment Progress of Immune Checkpoint Blockade Therapy for Glioblastoma.
    Zhang N; Wei L; Ye M; Kang C; You H
    Front Immunol; 2020; 11():592612. PubMed ID: 33329578
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current advances in PD-1/PD-L1 axis-related tumour-infiltrating immune cells and therapeutic regimens in glioblastoma.
    Shu C; Li Q
    Crit Rev Oncol Hematol; 2020 Jul; 151():102965. PubMed ID: 32442903
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Angiogenesis inhibitors in tackling recurrent glioblastoma.
    Hundsberger T; Reardon DA; Wen PY
    Expert Rev Anticancer Ther; 2017 Jun; 17(6):507-515. PubMed ID: 28438066
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glioblastoma precision therapy: From the bench to the clinic.
    Zhou Y; Wu W; Bi H; Yang D; Zhang C
    Cancer Lett; 2020 Apr; 475():79-91. PubMed ID: 32004571
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination immunotherapy strategies for glioblastoma.
    Chan HY; Choi J; Jackson C; Lim M
    J Neurooncol; 2021 Feb; 151(3):375-391. PubMed ID: 33611705
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Emerging therapies for glioblastoma: current state and future directions.
    Rong L; Li N; Zhang Z
    J Exp Clin Cancer Res; 2022 Apr; 41(1):142. PubMed ID: 35428347
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chimeric antigen receptor T-cell immunotherapy for glioblastoma: practical insights for neurosurgeons.
    Choi BD; Curry WT; Carter BS; Maus MV
    Neurosurg Focus; 2018 Jun; 44(6):E13. PubMed ID: 29852773
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Targeted therapy in glioblastoma: update and perspectives].
    Idbaih A; Duran-Peña A; Alentorn A
    Bull Acad Natl Med; 2015 Nov; 199(8-9):1323-1329. PubMed ID: 29874421
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glioblastoma multiforme: novel therapeutic targets.
    Muir M; Gopakumar S; Traylor J; Lee S; Rao G
    Expert Opin Ther Targets; 2020 Jul; 24(7):605-614. PubMed ID: 32394767
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Longitudinal heterogeneity in glioblastoma: moving targets in recurrent versus primary tumors.
    Schäfer N; Gielen GH; Rauschenbach L; Kebir S; Till A; Reinartz R; Simon M; Niehusmann P; Kleinschnitz C; Herrlinger U; Pietsch T; Scheffler B; Glas M
    J Transl Med; 2019 Mar; 17(1):96. PubMed ID: 30894200
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PD-1 Blockade in GBM: Uncovering Response Clues.
    Cancer Discov; 2019 Jun; 9(6):687-688. PubMed ID: 30979702
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vascular Targeting to Increase the Efficiency of Immune Checkpoint Blockade in Cancer.
    Georganaki M; van Hooren L; Dimberg A
    Front Immunol; 2018; 9():3081. PubMed ID: 30627131
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current Approaches and Challenges in the Molecular Therapeutic Targeting of Glioblastoma.
    Mooney J; Bernstock JD; Ilyas A; Ibrahim A; Yamashita D; Markert JM; Nakano I
    World Neurosurg; 2019 Sep; 129():90-100. PubMed ID: 31152883
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic Targeting of the Colorectal Tumor Stroma.
    Fridman WH; Miller I; Sautès-Fridman C; Byrne AT
    Gastroenterology; 2020 Jan; 158(2):303-321. PubMed ID: 31622621
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.